Stock ATYR ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company aTyr Pharma, Inc.

Equities

ATYR

US0021202025

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.56 USD +1.30% Intraday chart for aTyr Pharma, Inc. +4.70% +10.64%
06-05 ATyr Pharma, Inc. will Change its Ticker to ATYR. from LIFE CI
05-14 ATyr Pharma, Inc. Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT? Study in Pulmonary Sarcoidosis CI

Business Summary

aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).

Number of employees: 58

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Medicines
100.0 %
10 100.0 % 0 100.0 % -96.60%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
10 100.0 % 0 100.0 % -96.60%

Managers

Managers TitleAgeSince
Sanjay Shukla CEO
 Chief Executive Officer 52 29/03/16
Jill Broadfoot DFI
 Director of Finance/CFO 63 29/07/18
Lisa Carey CTO
 Chief Tech/Sci/R&D Officer - 31/05/15
Ashlee Dunston IRC
 Investor Relations Contact - 31/03/20
Peter Villiger PRN
 Corporate Officer/Principal - 30/04/16
Danielle Campbell HRO
 Human Resources Officer - 23/12/21
Robert W. Ashworth LAW
 General Counsel - 05/10/21
Leslie Nangle PRN
 Corporate Officer/Principal - -
Nancy Krueger LAW
 General Counsel 56 30/09/14
Andrew B. Cubitt PRN
 Corporate Officer/Principal - 31/08/11

Members of the board

Members of the board TitleAgeSince
Paul Schimmel FOU
 Founder 83 07/09/05
Tim Coughlin CHM
 Chairman 57 09/04/17
John Clarke BRD
 Director/Board Member 70 31/08/05
Sara Zaknoen BRD
 Director/Board Member 65 24/05/21
Sanjay Shukla CEO
 Chief Executive Officer 52 29/03/16
Jane Gross BRD
 Director/Board Member 67 27/06/19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 69,010,940 67,198,938 ( 97.37 %) 0 97.37 %

Shareholders

NameEquities%Valuation
Federated Global Investment Management Corp.
14.74 %
10,169,600 14.74 % 18 M $
Fidelity Management & Research Co. LLC
12.93 %
8,923,210 12.93 % 15 M $
Logos Global Management LP
4.492 %
3,100,000 4.492 % 5 M $
Vanguard Global Advisers LLC
3.843 %
2,652,157 3.843 % 5 M $
Tikvah Management LLC
3.566 %
2,460,833 3.566 % 4 M $
Citadel Securities GP LLC
2.758 %
1,903,346 2.758 % 3 M $
Woodline Partners LP
2.436 %
1,681,279 2.436 % 3 M $
Alyeska Investment Group LP
2.182 %
1,505,555 2.182 % 3 M $
Checkpoint Capital LP
2.096 %
1,446,477 2.096 % 3 M $
BlackRock Institutional Trust Co. NA
1.964 %
1,355,335 1.964 % 2 M $

Company contact information

aTyr Pharma, Inc.

10240 Sorrento Valley Road Suite 300

92121, San Diego

+858 731 8389

http://www.atyrpharma.com
address aTyr Pharma, Inc.(ATYR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for aTyr Pharma, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.54 USD
Average target price
24.6 USD
Spread / Average Target
+1,497.40%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ATYR PHARMA, INC. Stock aTyr Pharma, Inc.
+10.64% 106M
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.1B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.76B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 31.24B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.9B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 25.8B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.06B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 13.12B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.68B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ATYR Stock
  4. Company aTyr Pharma, Inc.